Sector News

Big Three Asia pharma markets poised to soar in 2015, reports say

March 16, 2015
Life sciences
The driving pharmaceutical segments of two of Asia’s pharmaceutical giants, India and Japan, are expected to grow at rates of nearly 11% and 8% respectively through the year 2019, and China is expected to record a near-12% increase in this year alone.
Limited information from a series of recent reports by various research companies focused on the overall China pharma market, India’s active pharmaceutical ingredients market and Japan’s generics markets for clues to what lies ahead for the industry in Asia’s three biggest markets.
One report pegged China’s pharmaceutical market to increase to $110.26 billion this year, for a growth of 11.7% in U.S. dollar terms. The nation’s overall healthcare industry was forecast to grow 13.5% this year.
Just off the China mainland, Hong Kong’s figures reported in another forecast had its pharmaceutical market increasing to nearly $1.7 billion this year, for an 8.5% growth, its overall healthcare market expanding by 7%.
Longer-term forecasts were published for India and Japan. India’s centered on its API market expected to achieve a compound annual growth rate of 10.76% from last year through 2019. Over a shorter period, through this year, its overall market was expected to achieve healthy growth, a report said.
Japan’s generics market outlook through 2019 looked a bit more reserved, with only an 8.16% CAGR from this year through 2019. In that report, Meiji Seika Pharma, Nichi-Iko, Nipro Pharma, Sawai, Teva ($TEVA) and Towa were named as the six leaders of that market segment.
Japan’s overall pharmaceutical industry was not expected to fare as well, according to other reports, one forecasting it to reach $79.8 billion by 2020, a CAGR of only 1.8%. Even as the government emphasizes prescribing generics instead of branded drugs, new drugs were expected to drive even that relatively small growth percentage.
One report also forecast Japan’s medical-device segment to grow at a 6.1% rate to $75 billion in 2020, crediting the nation’s universal health care coverage for the increase.
By EJ Lane

Related News

September 18, 2020

Eli Lilly, Amgen join forces to scale production of COVID-19 antibody cocktails

Life sciences

Months of fervid research have whittled away most potential options to treat patients with COVID-19, a group of antibody cocktails still hold promise. Eli Lilly believes so strongly in its contender that it’s […]

September 16, 2020

Takeda unveils new Boston R&D manufacturing center for cell therapy pipeline push

Life sciences

Japanese drugmaker Takeda has trumpeted its plan in recent years to cut billions of dollars in costs and pivot around oncology and rare diseases. A key part of that strategy […]

September 15, 2020

AstraZeneca, Oxford restart stalled COVID-19 test as Pfizer ramps up trial numbers for its vaccine

Life sciences

Just under a week after it stopped its key phase 3 pandemic vaccine test, AstraZeneca and the University of Oxford have been given the green light to restart in the […]